Table 3 Multilevel regression analysis of systolic blood pressure (SBP) in 1926 individuals from 438 Swedish families with hypertension
Model I (empty) | Model II | Model III | |
|---|---|---|---|
Fixed effects | |||
Intercept (mmHg) | |||
139.17 (0.64) | 141.78 (1.50) | 143.23 (1.66) | |
Regression coefficient (SE) | |||
Age (years) | - | 0.90 (0.03) | 0.90 (0.03) |
Sex (men vs. women) | - | -0.23 (0.81)NS | -0.20 (0.83)NS |
ACE inhibitors use (yes vs. no) Cohort | - | 4.51 (1.66) | 4.33 (1.62) |
Skara | - | Reference | Reference |
Malmö A | - | -7.64 (1.68) | -7.49 (1.67) |
Malmö B | - | -0.96 (1.60)NS | -0.87 (1.59)NS |
ACE gene I/D polymorphism | |||
II | - | - | Reference |
ID | - | - | -2.38 (1.06) |
DD | - | - | -1.48 (1.21)NS |
Random effects | |||
Variance (SE) | |||
Individual level | 511.50 (19.00) | 290.01 (11.17) | 290.32 (11.02) |
Familial intercept | 50.40 (12.34) | 30.22 (6.45) | 28.58 (7.56) |
Age-SBP slope | - | 0.04 (0.01) | 0.04 (0.01) |
ACE inhibitors-SBP slope | - | 142.46 (54.90) | 131.04 (48.83) |
Covariance (SE) | |||
Age-intercept | - | 0.99 (0.21) | 0.96 (0.23) |
ACE inhibitors-intercept | - | -22.62 (16.51) | -18.40 (14.62) |
Age-ACE inhibitors | - | -0.70 (0.61) | -0.66 (0.59) |
VPC (%) | |||
9 | See figure 2 | See figure 2 | |
Goddness of the fit | |||
DIC (MCM) | 16978 | 15898 | 15897 |